Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 1
2011 4
2012 2
2014 1
2015 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
CRTC2 as a novel prognostic biomarker for worse pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with prostate cancer.
Lee H, Lee M, Hong SK. Lee H, et al. Investig Clin Urol. 2019 Mar;60(2):84-90. doi: 10.4111/icu.2019.60.2.84. Epub 2019 Feb 19. Investig Clin Urol. 2019. PMID: 30838340 Free PMC article.
RESULTS: When we compared the expression of 18 metabolism-related genes between the high (4+3) and low pGS groups (3+4), there were significant differences in the expression of six genes (SREBP, SCD, FASN, ACLY, ECHS, and CRTC2; p<0.05). Among them, the subjects with lo …
RESULTS: When we compared the expression of 18 metabolism-related genes between the high (4+3) and low pGS groups (3+4), there were signific …
AMP-activated protein kinase promotes human prostate cancer cell growth and survival.
Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP. Park HU, et al. Mol Cancer Ther. 2009 Apr;8(4):733-41. doi: 10.1158/1535-7163.MCT-08-0631. Mol Cancer Ther. 2009. PMID: 19372545 Free PMC article.
AMPK was highly activated in 40% of human prostate cancer specimens examined. Endogenous AMPK was active in both the androgen-sensitive LNCaP cells and the androgen-independent CWR22Rv1 human prostate cancer cells. ...The evidence provided here is the first report t …
AMPK was highly activated in 40% of human prostate cancer specimens examined. Endogenous AMPK was active in both the androgen-sensiti …
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V, Festuccia C. Gravina GL, et al. Endocr Relat Cancer. 2011 Jul 1;18(4):385-400. doi: 10.1530/ERC-11-0045. Print 2011 Aug. Endocr Relat Cancer. 2011. PMID: 21551258
One of the major obstacles in the treatment of hormone-refractory prostate cancer (HRPC) is the development of chemo-resistant tumors. ...In addition, P529 synergized with DTX and CP. The strongest synergism was achieved when prostate cancer (PCa) cells were sequent …
One of the major obstacles in the treatment of hormone-refractory prostate cancer (HRPC) is the development of chemo-resistant tumors …
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Wang Y, et al. Oncogene. 2008 Nov 27;27(56):7106-17. doi: 10.1038/onc.2008.318. Epub 2008 Sep 8. Oncogene. 2008. PMID: 18776922 Free PMC article.
The mTOR (mammalian target of rapamycin) inhibitor rapamycin caused growth arrest in both androgen-dependent and androgen-independent prostate cancer cells; however, long-term treatment induced resistance to the drug. ...Thus, the combination of rapamycin and bicalutamide …
The mTOR (mammalian target of rapamycin) inhibitor rapamycin caused growth arrest in both androgen-dependent and androgen-independent pro …
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Fang Z, et al. J Biol Chem. 2012 Jan 13;287(3):2090-8. doi: 10.1074/jbc.M111.323303. Epub 2011 Dec 2. J Biol Chem. 2012. PMID: 22139837 Free PMC article.
Androgen receptor (AR) plays a central role in prostate cancer (PCa) growth, with androgen deprivation or AR down-regulation causing cell-cycle arrest and accumulation of the p27 cyclin-dependent kinase inhibitor. ...
Androgen receptor (AR) plays a central role in prostate cancer (PCa) growth, with androgen deprivation or AR down-regulation causing …
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
Muders MH, Zhang H, Wang E, Tindall DJ, Datta K. Muders MH, et al. Cancer Res. 2009 Aug 1;69(15):6042-8. doi: 10.1158/0008-5472.CAN-09-0552. Epub 2009 Jul 28. Cancer Res. 2009. PMID: 19638584 Free PMC article.
Long-term therapeutic success can only be achieved by identifying and targeting factors and signaling cascades that help these cells survive during stress. Both microarray and immunohistochemical analysis on human prostate cancer tissue samples have shown an increased expr …
Long-term therapeutic success can only be achieved by identifying and targeting factors and signaling cascades that help these cells survive …
PI3K/mTOR signaling regulates prostatic branching morphogenesis.
Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL. Ghosh S, et al. Dev Biol. 2011 Dec 15;360(2):329-42. doi: 10.1016/j.ydbio.2011.09.027. Epub 2011 Oct 8. Dev Biol. 2011. PMID: 22015718 Free PMC article.
In this study, we use a novel mesenchyme-free embryonic prostate culture system, newly available mTOR inhibitors and a conditional PTEN loss-of-function model to investigate the role of the interconnected PI3K and mTOR signaling pathways in prostatic organogenesis. …
In this study, we use a novel mesenchyme-free embryonic prostate culture system, newly available mTOR inhibitors and a conditional PT …
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M, Belfiore A. Malaguarnera R, et al. Endocrinology. 2014 Apr;155(4):1207-21. doi: 10.1210/en.2013-1925. Epub 2014 Jan 17. Endocrinology. 2014. PMID: 24437490 Free PMC article.
We, therefore, evaluated whether metformin may affect androgen-dependent IGF-IR up-regulation. In the AR(+) LNCaP prostate cancer cells, we found that metformin inhibits androgen-induced CRE activity and IGF-IR gene transcription. CRE activity requires the formation of a C …
We, therefore, evaluated whether metformin may affect androgen-dependent IGF-IR up-regulation. In the AR(+) LNCaP prostate cancer cel …
Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD. Xie Y, et al. Biochim Biophys Acta. 2015 Mar;1849(3):317-27. doi: 10.1016/j.bbagrm.2015.01.003. Epub 2015 Jan 21. Biochim Biophys Acta. 2015. PMID: 25615818 Free PMC article.
Furthermore, the CREB co-activator, cAMP-regulated transcriptional co-activator (CRTC2), is involved in CREB-mediated BCRP transcription: androgen depletion of LNCaP human prostate cancer cells increased both CREB phosphorylation and CRTC2 nuclear translocati …
Furthermore, the CREB co-activator, cAMP-regulated transcriptional co-activator (CRTC2), is involved in CREB-mediated BCRP transcript …
12 results